创新医疗(002173) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥193,334,481.58, a decrease of 3.98% compared to ¥201,344,535.99 in the same period last year[4] - The net profit attributable to shareholders was -¥13,937,418.26, representing a decline of 368.03% from -¥2,977,863.39 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥14,970,488.85, a decrease of 452.67% compared to -¥2,708,735.09 in the previous year[4] - Basic and diluted earnings per share were both -¥0.03, down 347.76% from -¥0.0067 in the previous year[4] - Net profit for the current period was a loss of CNY 13,890,668.31, compared to a loss of CNY 2,979,559.99 in the previous period[15] - The net profit attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, indicating a significant increase in losses[16] - The total comprehensive income attributable to the parent company was -13,937,418.26, compared to -2,977,863.39 in the previous period, reflecting a worsening financial position[16] - The basic and diluted earnings per share were both -0.03, compared to -0.0067 in the previous period, showing a decline in profitability[16] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥4,741,047.29, a significant increase of 126.84% from -¥17,663,752.00 in the same period last year[4] - Cash inflows from operating activities totaled 191,773,031.89, up from 182,904,706.98 in the previous period, indicating improved cash generation[17] - The net cash flow from operating activities was 4,741,047.29, a recovery from -17,663,752.00 in the previous period, suggesting operational improvements[18] - Cash inflows from investing activities were 55,025,416.74, down from 304,959,178.42 in the previous period, indicating reduced investment activity[18] - The net cash flow from investing activities was 21,058,502.54, a significant decrease from 288,142,403.29 in the previous period, reflecting a shift in investment strategy[18] - The net cash flow from financing activities was 486,724.90, down from 10,452,995.48 in the previous period, indicating a reduction in financing activities[18] - The ending cash and cash equivalents balance was 143,789,708.17, down from 529,951,281.78 in the previous period, showing a decrease in liquidity[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,164,041,606.40, a decrease of 1.81% from ¥2,203,947,708.41 at the end of the previous year[4] - Total operating costs increased to CNY 205,240,260.34, up 1.0% from CNY 202,244,492.52[15] - Total assets decreased to CNY 2,164,041,606.40 from CNY 2,203,947,708.41, reflecting a decline of 1.8%[14] - Total liabilities decreased to CNY 400,833,433.03 from CNY 426,848,866.73, a reduction of 6.1%[13] - Current assets totaled CNY 566,946,305.73, down 5.3% from CNY 598,852,540.99[12] - Non-current assets totaled CNY 1,597,095,300.67, a slight decrease from CNY 1,605,095,167.42[13] - The company's retained earnings showed a deficit of CNY 1,412,129,160.15, worsening from a deficit of CNY 1,398,191,741.89[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 68,155[9] Non-Recurring Items - The company reported a non-recurring gain of ¥1,033,070.59, primarily from fair value changes of financial assets and liabilities[5] - The decline in net profit was attributed to changes in payment methods for rehabilitation diseases and dynamic adjustments in medical insurance payment standards[7] Audit Status - The first quarter report was not audited, which may affect the reliability of the financial data presented[19]